Imperial Innovations Group plc has led a £3.0 million investment in portfolio company Abingdon Health Ltd alongside existing investors.
In conjunction with the investment round, Abingdon Health has appointed Chris Yates as CEO. Chris was previously CFO of AIM-listed Immunodiagnostic Systems Holdings PLC and AIM-listed Cozart plc.
Abingdon Health Ltd is a UK based in vitro diagnostic group. This investment follows the commercial launch of Abingdon Health's Seralite®- FLC device, which is the world's first rapid diagnostic device in multiple myeloma, in March 2015.
To read the full article please visit www.abingdonhealth.com/3m-fundraising-appointment-of-chairman-and-ceo/